product
Abcam MMP Activity Assay Kit (Fluorometric – Red, ab112147)
23 April 2015 | By Abcam
MMP Activity Assay Kit (Fluorometric - Red, ab112147) uses a fluorescence resonance energy transfer (FRET) peptide as a MMP substrate...
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
news
Blueprint Medicines presents preclinical data demonstrating significant anti-tumour activity of BLU-285 in treatment-resistant GIST
20 April 2015 | By Victoria White
New preclinical data demonstrates that BLU-285 has significant anti-tumour activity in treatment-resistant models of gastrointestinal stromal tumours (GIST)...
article
Drug Targets In-Depth Focus 2015
9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.
In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...
product
Avacta Anti-diUbiquitin K6-linkage Affimer (44-29)
1 April 2015 | By Avacta Life Sciences
Lys-6-linked chains may be involved in DNA repair. Affimers are engineered to outperform antibodies and aptamers...
product
Avacta Anti-diUbiquitin K33-linkage Affimer (48-1)
1 April 2015 | By Avacta Life Sciences
Lys-33-linked chains are believed to be involved in kinase modification. Affimers are engineered to outperform antibodies and aptamers...
product
Avacta Anti-diUbiquitin K48-linkage Affimer (36-16)
1 April 2015 | By Avacta Life Sciences
Lys-48-linked chains are involved in protein degradation via the proteasome. Affimers are engineered to outperform antibodies and aptamers...
product
Avacta Anti-Human SUMO1 Affimer (HS1-A1)
1 April 2015 | By Avacta Life Sciences
A ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer...
news
ZoBio and Domainex join forces to deliver crucial drug target information to support FORMA therapeutics’ drug discovery programs
10 December 2014 | By ZoBio and Domainex
ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
news
Cancer drug discovery system is broken, global summit hears
24 October 2014 | By The Institute of Cancer Research, London
Leading expert calls for major changes to restock pipeline with innovative cancer treatments...
article
Synthetic macrocyclic receptors as tools in drug delivery and drug discovery
Macrocyclic compounds (see Figure 1) have fascinated medicinal chemists for generations. The first ones which have been characterised are the naturally occurring cyclodextrins (CDs), cyclic oligomers of glucose, which can be obtained by bacterial synthesis from starch. Calixarenes (CXs) were among the first man-made macrocycles, followed by crown ethers (Pedersen,…
news
MRC Technology and AstraZeneca renew collaboration to identify novel targets for discovery research
3 July 2014 | By MRC Technology
Initiative brings together global expertise to share compound libraries and streamline drug discovery...
news
Sanford-Burnham and Daiichi Sankyo form alliance to study novel drug targets in cardiovascular-metabolic diseases
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
article
Building GPCR screening cascades for lead generation
Although this target class is already heavily investigated, there are still a significant number of opportunities for discovery of novel drugs targeting additional GPCRs. In this review, scientists from AstraZeneca R&D discuss the general build-up of GPCR screening cascades for discovery of chemical leads that can be further developed into…
news
Five Prime Therapeutics and Bristol-Myers Squibb sign collaboration agreement to discover novel immuno-oncology therapies for two immune checkpoint pathways
17 March 2014 | By Bristol-Myers Squibb
Five Prime Therapeutics, Inc. and Bristol-Myers Squibb Company announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies...
